MEREDITH VEAZEY: Open Payments
NPI 1598122715 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,583 in 71 payments from 24 companies in 2025. Trend: 2023 $1,144 · 2024 $1,596 · 2025 $1,583
Food & beverage: $1,583
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 7 | $245 |
| Janssen Biotech, Inc. | 10 | $229 |
| Novartis Pharmaceuticals Corporation | 8 | $161 |
| Exelixis Inc. | 7 | $151 |
| E.R. Squibb & Sons, L.L.C. | 6 | $112 |
| Merck Sharp & Dohme LLC | 5 | $101 |
| Celgene Corporation | 4 | $99 |
| AstraZeneca Pharmaceuticals LP | 3 | $52 |
| Daiichi Sankyo Inc. | 2 | $51 |
| PFIZER INC. | 2 | $47 |
Products named: JAKAFI, CABOMETYX, RYBREVANT, OPDIVO, Fabhalta, KEYTRUDA, Enhertu, POMALYST.
Industry payments across AL — which companies pay providers there.
